OBJECTIVE -Transforming growth factor (TGF)-1 is overexpressed in diabetes as a consequence of hyperglycemia and the creation of early glycated end products and may be responsible for the characteristic structural renal changes associated with diabetes. We sought to examine the role of both urinary and circulating TGF-1 and its promoter Amadori albumin in the vascular complications of type 1 diabetes.
RESEARCH DESIGN AND METHODS -The present article reports on a nested casecontrol study from the EURODIAB Prospective Complications Study of Europeans with type 1 diabetes. Case subjects (n ϭ 356) were all individuals with one or more complications of diabetes; control subjects (n ϭ 185) were all individuals with no evidence of complications.RESULTS -Urinary TGF-1 and Amadori albumin were elevated in patients with micro-or macroalbuminuria. Standardized regression effects (SREs) for macroalbuminuria versus normoalbuminuria were 2.45 (95% CI 1.88 -3.18, P ϭ 0.0001 for urinary TGF-1) and 1.67 (1.34 -2.07, P ϭ 0.001 for Amadori albumin). The SRE for urinary TGF-1 remained statistically significant when adjusted for HbA 1c , Amadori albumin, and blood pressure. Circulating TGF-1 was elevated in individuals with proliferative retinopathy compared with individuals without retinopathy (SRE 1.29 [1.07-1.550], P ϭ 0.007). This result was attenuated to 1.16 (0.95-1.43, P ϭ 0.2) in the multivariate model, largely because of HbA 1c .CONCLUSIONS -Elevated levels of urinary TGF-1 in macroalbuminuria were associated with elevations in Amadori albumin and HbA 1c and also in blood pressure. In contrast, only circulating TGF-1 was related to proliferative retinopathy, and HbA 1c largely accounted for this. These findings may indicate novel pathways for understanding mechanisms and therapeutic interventions.
Diabetes Care 25:2320 -2327, 2002I mprovements in glycemic control and the greater use of antihypertensive therapy should eventually have a beneficial impact on the incidence of severe nephropathy in type 1 diabetes. However, early disease, such as microalbuminuria and macroalbuminuria, will continue to occur because glycemic control cannot wholly prevent the progression of albuminuria, and there is currently little evidence that antihypertensive use in normotensive normoalbuminuric patients is of clinical value (1). Both microalbuminuria and macroalbuminuria significantly increase the risk of morbidity and mortality from coronary heart disease and are strong predictors of subsequent severe renal disease (2). Prevention of the early stages of diabetic renal disease and reduction in progression should now be priorities, but these steps require a more complete understanding of the etiology to identify suitable targets for intervention.Diabetic nephropathy is characterized by hypertrophy of the glomerular and tubuloepithelial structures and thickening of the glomerular and tubular basement membrane, due largely to the effects of hyperglycemia (3). The cytokine transforming growth factor (TGF)-1 appears to be a key mediator f...